FoxHollow Delays Pursuit Of SilverHawk Coronary Artery Disease Indication
This article was originally published in The Gray Sheet
Executive Summary
FoxHollow has once again delayed the start of a clinical trial to study the treatment of coronary artery disease with the SilverHawk plaque excision system